Claude Nicaise - Net Worth and Insider Trading

Claude Nicaise Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Claude Nicaise owns 3 companies in total, including Sarepta Therapeutics Inc (SRPT) , Chemomab Therapeutics Ltd (CMMB) , and Gain Therapeutics Inc (GANX) .

Click here to see the complete history of Claude Nicaise’s form 4 insider trades.

Insider Ownership Summary of Claude Nicaise

Ticker	Comapny	Transaction Date	Type of Owner
SRPT	Sarepta Therapeutics Inc	2015-06-02	director
CMMB	Chemomab Therapeutics Ltd	2021-03-16	director
GANX	Gain Therapeutics Inc	2021-03-17	director

Claude Nicaise Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Claude Nicaise Ownership Network

Ownership Network List of Claude Nicaise

No Data

Ownership Network Relation of Claude Nicaise

Claude Nicaise Owned Company Details

What does Sarepta Therapeutics Inc do?

Who are the key executives at Sarepta Therapeutics Inc?

Claude Nicaise is the director of Sarepta Therapeutics Inc. Other key executives at Sarepta Therapeutics Inc include Chief Financial Officer Ian Michael Estepan , Chief Tech Ops Officer Bilal Arif , and SVP & General Counsel Ryan Edward Brown .

Sarepta Therapeutics Inc (SRPT) Insider Trades Summary

Over the past 18 months, Claude Nicaise made no insider transaction in Sarepta Therapeutics Inc (SRPT). Other recent insider transactions involving Sarepta Therapeutics Inc (SRPT) include a net purchase of 105,570 shares made by Michael Andrew Chambers , a net sale of 40,957 shares made by Ryan Edward Brown , and a net sale of 30,000 shares made by Wigzell Hans Lennart Rudolf .

In summary, during the past 3 months, insiders sold 5,985 shares of Sarepta Therapeutics Inc (SRPT) in total and bought 37,038 shares, with a net purchase of 31,053 shares. During the past 18 months, 99,430 shares of Sarepta Therapeutics Inc (SRPT) were sold and 180,795 shares were bought by its insiders, resulting in a net purchase of 81,365 shares.

Sarepta Therapeutics Inc (SRPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sarepta Therapeutics Inc Insider Transactions

No Available Data

What does Chemomab Therapeutics Ltd do?

Who are the key executives at Chemomab Therapeutics Ltd?

Claude Nicaise is the director of Chemomab Therapeutics Ltd. Other key executives at Chemomab Therapeutics Ltd include 10 percent owner Orbimed Israel Biofund Gp Limited Partnership , director & 10 percent owner & Chief Executive Officer George Adi Mor , and Chief Medical Officer Matthew Bejosa Frankel .

Chemomab Therapeutics Ltd (CMMB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Chemomab Therapeutics Ltd (CMMB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Chemomab Therapeutics Ltd (CMMB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Chemomab Therapeutics Ltd (CMMB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chemomab Therapeutics Ltd Insider Transactions

No Available Data

What does Gain Therapeutics Inc do?

Who are the key executives at Gain Therapeutics Inc?

Claude Nicaise is the director of Gain Therapeutics Inc. Other key executives at Gain Therapeutics Inc include Chief Operating Officer Matthias Alder , Chief Financial Officer Charles Evan Ballantyne , and Principal Accounting Officer Gianluca Fuggetta .

Gain Therapeutics Inc (GANX) Insider Trades Summary

Over the past 18 months, Claude Nicaise made no insider transaction in Gain Therapeutics Inc (GANX). Other recent insider transactions involving Gain Therapeutics Inc (GANX) include a net sale of 2,026 shares made by Matthias Alder , a net purchase of 50,000 shares made by Khalid Islam , and a net purchase of 30,000 shares made by Jeffrey Scott Riley .

In summary, during the past 3 months, insiders sold 0 shares of Gain Therapeutics Inc (GANX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,026 shares of Gain Therapeutics Inc (GANX) were sold and 111,400 shares were bought by its insiders, resulting in a net purchase of 109,374 shares.

Gain Therapeutics Inc (GANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gain Therapeutics Inc Insider Transactions

No Available Data

Claude Nicaise Mailing Address

Above is the net worth, insider trading, and ownership report for Claude Nicaise. You might contact Claude Nicaise via mailing address: 215 First Street, Suite 415, Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.